OpGen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 3.42 million compared to USD 2.61 million a year ago. Net loss was USD 32.67 million compared to USD 37.28 million a year ago.
OpGen is a Maryland-based biotechnology company that researches and develops molecular diagnostic therapeutics for the treatment of infectious diseases.